Medical Sales Representative Interview Questions

I start by doing my homework before every visit. I check prescribing patterns, look at what clinical meetings the practice has attended recently, and try to identify a genuine clinical need I can help with rather than walking in with a generic pitch. When I get the appointment, I respect the time constraint from the start: I lead with something relevant to their patients, not to my quota. Over time, the consistency of showing up with useful information rather than just product messages is what builds the relationship. I also stay in touch between visits, sharing relevant clinical papers or congress highlights when something is genuinely useful to them. The reps who last in this role are the ones who make the doctor or pharmacist feel that the interaction added something to their practice, not just ticked a call box for me.

I have a weekly routine for this. I follow key journals in the therapeutic area and set up PubMed alerts for the main compounds I work with, so I see new trial data as it publishes. I attend all the internal medical training sessions my company runs, and I treat congress season seriously: I prepare before major events, attend symposia where I can, and debrief with the medical affairs team afterwards to understand what the data means clinically, not just commercially. I also find that having real clinical conversations with specialists deepens my understanding in a way that reading alone does not. When a cardiologist tells me how they actually use the drug in practice, that context shapes how I talk about it with GPs in a much more credible way.

I welcome those conversations because they tell me the HCP is engaged and thinking critically. My first move is always to listen properly and understand exactly what they are challenging: is it the study design, the patient population, a specific endpoint, or a comparison to a competitor they prefer? Once I understand the objection, I respond with what the data actually says, and if there is a limitation they have identified that is real, I acknowledge it honestly. I never try to talk someone out of a valid clinical concern. If the question goes beyond what I can answer credibly in the room, I say so and offer to come back with a response from our medical affairs team. Trying to bluff a specialist always destroys trust faster than admitting you need to check.

I segment my territory into three tiers based on a combination of prescribing volume, growth potential, and how receptive the HCP is to discussion. High-potential accounts that are currently under-penetrated get the most frequent visits and the most preparation. Established accounts that are already strong for the product still need regular contact to maintain loyalty and address any clinical questions, but the visit frequency is lower. Accounts with very low potential or where there is a genuine clinical reason the product is not a fit get minimal time. I track all of this in the CRM and review my plan monthly against actual call data and sales figures, adjusting when something is not working. Territory planning is not a quarterly exercise: it is a rolling process that responds to what the data shows.

In my previous role, I had a consultant cardiologist who had been on my territory for two years and had never prescribed our product despite it being well-suited to a significant portion of his patient population. Previous reps had tried multiple times and got nowhere. I requested a longer meeting, not a detail visit, and came in asking about his patient pathway rather than talking about the product at all. He told me that his concern was around a specific contraindication in patients with renal impairment, which he saw a lot. I went back to medical affairs, got a detailed clinical analysis of the renal subgroup data from our trial, and returned with that specific data. He started prescribing within six weeks. The account grew to become my second-largest by the end of that year. The lesson was that the block was always clinical, not commercial.

A GP I had a good relationship with asked me to arrange a dinner event for his practice team and invited me to include a speaker fee for a colleague he wanted to present. The request felt off immediately: the colleague had no prior relationship with our company and the event format did not match our approved programme structures. I told the GP directly that I could not arrange something outside our compliance framework, and I explained why rather than just saying no. I offered to organise a properly structured lunch meeting with an approved faculty speaker instead. He was initially frustrated, but he respected the honesty. I escalated the original request to my line manager and compliance team the same day, so there was a clear record. Protecting that relationship long-term was more important than a short-term win that could have put my company and the GP at risk.

In my last role I finished the year at 118% of target, which was the highest in my region. The product was a second-line treatment in a competitive diabetes category. I identified early in the year that GPs were defaulting to the first-line agent even in patients who had already failed it, largely out of habit rather than clinical rationale. I built a call plan focused specifically on that patient sub-type and developed a short conversation piece around the clinical pathway guidelines that made it easy for GPs to see exactly when our product was indicated. I ran ten small group practice meetings over the year to share the pathway data, which generated more engagement than individual visits. By Q3 I had shifted the prescribing pattern in six of my top ten practices. The work was systematic and planned from the start of the year, not a push in the final quarter.

I research the competitor's position first: what the clinical data actually shows, what its limitations are, and why the specialist might favour it. I also look at what patient types the specialist sees most frequently, because that shapes which part of our data is most relevant. In the visit I do not lead with a head-to-head comparison, since that tends to put people on the defensive. Instead I ask about specific patient cases where the specialist finds the current treatment falls short, which opens a clinical conversation on the gap rather than a commercial debate about which product is better. I then position our data around exactly those patient types. If the specialist raises the competitor directly, I address it factually and within the bounds of what the approved materials say. I always leave something clinically relevant rather than just a promotional leave-piece.

The first thing I do is separate the headline from the detail. In a five-minute window with a GP, I focus on one primary endpoint and what it means for the type of patient they see in their practice, not the full trial summary. I translate statistical language into clinical terms: instead of "a statistically significant reduction in HbA1c of 0.8% versus placebo," I say "in a patient who is already on metformin and still running an HbA1c of 8.5, this gives you an additional reduction you can expect within 12 weeks." I also flag the study population honestly so the GP can judge how well it matches their patients. With specialists I go deeper into trial design and subgroup data, because they will ask. The skill is knowing which level of detail fits the conversation, and reading that quickly.

Effective territory planning starts with a data audit at the beginning of the year: prescribing data from the CRM, any market data we have access to, and my own qualitative assessment of each account from the previous year. I classify accounts by tier, set visit frequency targets per tier, and map those targets against the number of available call days in the year to make sure the plan is achievable. I build it into my CRM so every visit is logged against the account tier and the call objective. Monthly I pull a report comparing planned versus actual calls and prescribing trends, and I adjust the plan for the following four to six weeks based on what I see. I treat the plan as a living document. If a previously low-tier account starts showing growth, I move resources toward it quickly rather than waiting for the annual review cycle to catch up.